- 1.
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402–14. [PubMed][CrossRef]
- 2.
Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795–803. [PubMed][CrossRef]
- 3.
Åsberg AS, Samdal Ø, Thomsen J et al. Norsk Nyreregister. Årsrapport for 2020 med plan for forbedringstiltak. 2021. https://www.kvalitetsregistre.no/sites/default/files/2021-06/Nyrereg.%20A%CC%8Arsrapport%202020.pdf Lest 5.5.2022.
- 4.
Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 2018; 38: 435–42. [PubMed][CrossRef]
- 5.
Zhang H, Barratt J. Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol 2021; 43: 707–15. [PubMed][CrossRef]
- 6.
Knoop T, Vikse BE, Svarstad E et al. Mortality in patients with IgA nephropathy. Am J Kidney Dis 2013; 62: 883–90. [PubMed][CrossRef]
- 7.
Soares MFS, Roberts ISD. Histologic classification of IgA nephropathy: past, present, and future. Semin Nephrol 2018; 38: 477–84. [PubMed][CrossRef]
- 8.
Knoop T, Vikse BE, Mwakimonga A et al. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 2017; 32: 1841–50. [PubMed][CrossRef]
- 9.
Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534–45. [PubMed][CrossRef]
- 10.
Trimarchi H, Barratt J, Cattran DC et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 2017; 91: 1014–21. [PubMed][CrossRef]
- 11.
Haaskjold YL, Bjørneklett R, Bostad L et al. Utilizing the MEST score for prognostic staging in IgA nephropathy. BMC Nephrol 2022; 23: 26. [PubMed][CrossRef]
- 12.
Sukcharoen K, Sharp SA, Thomas NJ et al. IgA nephropathy genetic risk score to estimate the prevalence of IgA nephropathy in UK Biobank. Kidney Int Rep 2020; 5: 1643–50. [PubMed][CrossRef]
- 13.
Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol 2019; 23: 26–31. [PubMed][CrossRef]
- 14.
Schena FP, Anelli VW, Trotta J et al. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy (suppl tabell 1, s. 8). Kidney Int 2021; 99: 1179–88. [PubMed][CrossRef]
- 15.
Wen D, Tang Y, Tan L et al. Sex disparities in IgA nephropathy: a retrospective study in Chinese patients. Int Urol Nephrol 2021; 53: 315–23. [PubMed][CrossRef]
- 16.
Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177–83. [PubMed][CrossRef]
- 17.
Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157–63. [PubMed][CrossRef]
- 18.
Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373: 2225–36. [PubMed][CrossRef]
- 19.
Lunde Haaskjold Y, Rivedal M, Gjærde Lura N et al. MO268: Use of Corticosteroids in a Norwegian Cohort of Patients with IGA Nephropathy and Rapid Progression to End-Stage Renal Disease. Nephrol Dial Transplant 2022; 37 (Supplement_3): gfac067.067. [CrossRef]
- 20.
Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol 2021; 43: 717–28. [PubMed][CrossRef]
- 21.
Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100: 753–79. [PubMed][CrossRef]
- 22.
Cattran DC, Feehally J, Cook HT et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139–274.
- 23.
Thompson A, Carroll K, Inker LA et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14: 469–81. [PubMed][CrossRef]
- 24.
Fellström BC, Barratt J, Cook H et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389: 2117–27. [PubMed][CrossRef]
- 25.
Selvaskandan H, Cheung CK, Muto M et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 2019; 23: 577–88. [PubMed][CrossRef]
- 26.
Wheeler DC, Toto RD, Stefánsson BV et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100: 215–24. [PubMed][CrossRef]
- 27.
Barbour SJ, Coppo R, Zhang H et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019; 179: 942–52. [PubMed][CrossRef]
- 28.
Barbour SJ, Canney M, Coppo R et al. Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney Int 2020; 98: 1009–19. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
IgA nefropati og behandling
10.11.2022Takk til forfatterne for en flott oversiktsartikkel (1). De nevner imidlertid ikke omega-3 flerumettede fettsyrer (PUFA) som en behandlingsmulighet ved IgA nefropati. Jeg er klar over at det er delte meninger om dette er en effektiv behandling, og at mange…